The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Can Certain DMARDs Treat Dementia?

Can Certain DMARDs Treat Dementia?

April 26, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Orawan Pattarawimonchai / shutterstock.com

Orawan Pattarawimonchai / shutterstock.com

In the complex web of interactions between systemic inflammatory response, rheumatic disease and disease-modifying anti-rheumatic drugs (DMARDs), what is the potential for using rheumatologic therapies to treat other medical conditions linked to inflammation? Some medical researchers have looked at cardiac conditions, and others have examined the overlap with Alzheimer’s disease and other dementias.

You Might Also Like
  • Socioeconomic Factors Contribute to Inconsistent Use of DMARDs Among Patients with RA
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease
Explore This Issue
April 2018
Also By This Author
  • Rheumatoid Arthritis Research Advances

Positive effects have resulted from using methotrexate (MTX) and other tumor necrosis factor (TNF) inhibitors to treat athero­sclerosis, an inflammatory heart disease. MTX has been shown to reduce all-cause cardio­vascular disease (CVD), heart failure and CVD mortality, as well as acute myo­cardial infarction and stroke.1 CIRT (the Cardiovascular Inflammation Reduction Trial), a randomized clinical trial funded by the National Heart, Lung, and Blood Institute to enroll 7,000 men and women in the U.S. and Canada, is testing whether low-dose MTX reduces rates of myocardial infarction, stroke and cardiovascular death. The Consortium of Rheumatology Researchers of North America’s CERTAIN (Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions) sub-study is an ongoing prospective cohort of adult patients with rheumatoid arthritis (RA).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Chang et al observed that the prevalence of hypertension, coronary artery disease (CAD), stroke and depression was significantly higher in the RA cohort than in a non-RA group, a finding consistent with previous studies.2 “Diabetes, hypertension, CAD, head injury, COPD [chronic obstructive pulmonary disease], stroke, CHF [congestive heart failure] and depression are also known risk factors for dementia,” they note. TNF plays a crucial role in the pathogenesis of RA. A study by Chou et al from 2016 documented an increased risk of Alzheimer’s in a studied population of patients with RA, as well as potential lower risk for those exposed to etanercept.3

Dr. Edwards

Dr. Edwards

A recent observational study reported that prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) reduced the risk of dementia in patients with RA. The Baltimore Longitudinal Study of Aging also found a lower risk of Alzheimer’s disease among users of NSAIDs.4 Now, a team of researchers in the U.K. is gathering evidence of the effects of older patients receiving DMARDs for RA on the incidence of dementia.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Dementia researchers have tried to develop treatments for Alzheimer’s disease, which by and large have not been very effective,” says one of the U.K. researchers, Christopher J. Edwards, MD, FRCP, a consultant rheumatologist and honorary chair of clinical rheumatology at University Hospital in Southampton, England. Dementia is an umbrella term for a range of conditions associated with cognitive impairment, with various hypotheses for its root causes in Alzheimer’s disease. Evidence exists that dementia is at least in part an inflammatory condition. Evidence suggesting that dementia is more common in patients with chronic inflammation like that seen in RA is not widely known among rheumatologists because they may not be looking for it, he says.

Pages: 1 2 3 4 5 | Single Page

Filed Under: DMARDs & Immunosuppressives Tagged With: Alzheimer's Disease, dementia, DMARDsIssue: April 2018

You Might Also Like:
  • Socioeconomic Factors Contribute to Inconsistent Use of DMARDs Among Patients with RA
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease
  • DMARDs & Biologics Info for Rheumatology Nurses

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.